The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/152638

Please be advised that this information was generated on 2020-04-30 and may be subject to change.
Quantitative Motor Performance and Sleep Benefit in Parkinson Disease

Merel M. van Gilst, MSc; Petra van Mierlo, MSc; Bastiaan R. Bloem, MD, PhD; Sebastiaan Overeem, MD, PhD

1Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, the Netherlands; 2Sleep Medicine Centre Kempenhaeghe, Heeze, the Netherlands; 3Eindhoven University of Technology, Eindhoven, the Netherlands

Study Objectives: Many people with Parkinson disease experience “sleep benefit”: temporarily improved mobility upon awakening. Here we used quantitative motor tasks to assess the influence of sleep on motor functioning in Parkinson disease.

Design: Eighteen Parkinson patients with and 20 without subjective sleep benefit and 20 healthy controls participated. Before and directly after a regular night sleep and an afternoon nap, subjects performed the timed pegboard dexterity task and quantified finger tapping task. Subjective ratings of motor functioning and mood/vigilance were included. Sleep was monitored using polysomnography.

Results: On both tasks, patients were overall slower than healthy controls (night: F2,55 = 16.938, P < 0.001; nap: F2,55 = 15.331, P < 0.001). On the pegboard task, there was a small overall effect of night sleep (F1,55 = 9.695, P = 0.003); both patients and controls were on average slightly slower in the morning. However, in both tasks there was no sleep*group interaction for nighttime sleep nor for afternoon nap. There was a modest correlation between the score on the pegboard task and self-rated motor symptoms among patients (rho = 0.233, P = 0.004). No correlations in task performance and mood/vigilance or sleep time/efficiency were found.

Conclusions: A positive effect of sleep on motor function is commonly reported by Parkinson patients. Here we show that the subjective experience of sleep benefit is not paralleled by an actual improvement in motor functioning. Sleep benefit therefore appears to be a subjective phenomenon and not a Parkinson-specific reduction in symptoms.

Keywords: sleep, Parkinson disease, sleep benefit, pegboard task, finger tapping, nap


INTRODUCTION

Sleep disorders are highly prevalent among patients with Parkinson disease. However, there are also reports of Parkinson patients experiencing a beneficial effect of sleep. Upon awakening in the morning, many patients experience an improved mobility as if they are in a medication-induced “on” state, contrary to what would be expected after a night without medication. This intriguing phenomenon is known as “sleep benefit.”

Some Parkinson patients are even able to delay or skip their morning dose of medication because of this sleep benefit. According to questionnaire studies, the prevalence of sleep benefit is consistently reported to be quite high, with 33% to 55% of Parkinson patients reporting to experience sleep benefit.

Studies using objective measures of sleep benefit are limited in number so far. A few studies assessed motor performance using the Unified Parkinson’s Disease Rating Scale (UPDRS) motor scale. In the Högl study, there was no difference in morning function between patients with and without subjective sleep benefit. However, comparisons between evening and morning status showed an improvement in motor function in those patients reporting sleep benefit, and a deterioration in patients without.

Although widely used, the UPDRS strongly depends on the observer and is time-consuming. Attractive alternative measures for motor function are available, such as the pegboard dexterity test, which is a fast and sensitive instrument to objectively and quantitatively evaluate motor dysfunction in Parkinson disease. Additionally, bradykinesia can be quantified using an alternating finger tapping task (digitography).

METHODS

Patients

Patients were recruited from a cohort of 240 Parkinson patients who completed both a questionnaire and a diary on sleep benefit. Patients filled out a daily symptom diary before and directly after sleep for 7 consecutive days, in which they subjectively rated different aspects of their motor functioning (see measures section for more details). A night with a positive change of at least one point (better functioning in the morning than in the evening) was regarded as a “sleep benefit-night.” The same approach was used for daytime naps. Patients were classified as having sleep benefit, when sleep benefit was present after ≥ 2 nights or 2 naps during the 7-day period. We also used a questionnaire that asked patients whether or not they experienced a sleep benefit upon awakening.
not they experienced any sleep benefit, based on the recently revised definition of sleep benefit, as follows: “Sleep benefit is the experience of a temporary decrease in Parkinson’s symptoms upon awakening after a period of sleep (night or daytime), before drug intake; the patient is feeling as good as ‘on’ (or better).” More details on both the diary and questionnaire can be found in the paper describing the results of these instruments.

We estimated a required number of subjects based on an effect size of one-third of the effect size to differentiate between healthy controls and early diagnosed Parkinson patients. With a correlation between consecutive pegboard test results of 0.93, an α value of 0.05 and β of 0.8, this yielded a required group size of approximately 17 evaluable subjects. We were able to include 18 Parkinson patients who clearly reported to experience a subjective improvement in motor functioning after night and/or daytime sleep. In addition, we selected 20 patients who reported no improvement at all after sleep.

We included patients with idiopathic Parkinson disease, defined according to the UK Brain Bank criteria, Hoehn & Yahr stage I-III. Exclusion criteria included current major psychiatric diagnosis, deep brain surgery for Parkinson disease, neurological disease other than Parkinson disease and chronic daily use of hypnotics. All patients were used to taking an afternoon nap, so they felt able to sleep during the nap period in the experiment.

Healthy Controls
Twenty healthy controls participated. These controls were recruited in the older healthy population (40–75 years old). Controls were not necessarily habitual nappers; however, they all indicated that they were able to sleep during the day. Exclusion criteria were current neurologic or psychiatric diagnosis and chronic daily use of hypnotics.

Consent
The study was approved by the institutional medical ethical committee. All participants gave their written informed consent before participating. Participants received a financial compensation for their participation in this study.

Study Design

Procedure
Figure 1 shows the study design. In the early evening, subjects arrived at the sleep lab. First they were trained extensively in the pegboard dexterity task and finger tapping task. Before bedtime, a test session was completed (test 1). All test sessions included the pegboard dexterity task, finger tapping task, and subjective rating scales on motor functioning and mood/vigilance, described below. The order of administration was counterbalanced across subjects.

Subjects spent the night at the sleep lab. On awakening in the morning, a test session was completed (test 2). For all post-sleep measures, the tasks were administered 15 minutes after awakening to reduce the possible influence of sleep inertia. Later in the morning, a neuropsychological test battery was completed.

In the early afternoon, all subjects took an afternoon nap directly followed by a test session after awakening (test 4). We applied a crossover design, in which the reference examination (test 3) was done either before the nap or after an additional period of active wakefulness, when possible sleep benefit effects had disappeared. The order of examination was randomized and counterbalanced in all groups. The results of test 3 did not differ, either when this test was performed before the nap or after rest. Therefore, these data were pooled in the analyses.

Night Sleep
Subjects went to bed at 23:00 and slept until they woke up spontaneously to reduce the possible effects of residual sleepiness (sleep inertia) on morning testing. However, when not yet awake at 07:30, they were awakened by the experimenter. After 06:00, when a subject woke up and did not fall asleep again within 15 minutes, the night sleep period was terminated and post sleep tasks were started.

Nap
For the afternoon nap, subjects had a 90-min nap opportunity. The subjects slept until they woke up spontaneously or were awakened by the experimenter when the 90 min were over. When a subject slept a cumulative minimum of 15 min
and did not fall asleep again within 15 min, the nap period was terminated and post sleep tasks were started.

**Rest Period**

During the rest period, subjects could perform their normal afternoon activities for 90 min. They were, for example, allowed to talk to the experimenter, read a book, or take a short walk, but they had to stay at the lab. Subjects were not allowed to sleep during the rest period.

**Medication**

On the day of arrival in the sleep lab for the night of the study, patients did not take their Parkinson medication after 13:00. When they arrived in the sleep lab, they were thus already in the “off” state. After the pre-night test sessions, patients took their normal bedtime dose of Parkinson medication before the night (23:00), to increase the probability of a normal night of sleep. When patients did not take medication at bedtime, they postponed their evening medication (i.e., dinner time) to the night. This was the case for 10 patients (55.5%) with sleep benefit and 6 (30%) patients without sleep benefit. All dopaminergic medication was converted into the L-dopa equivalent dose (LED), using the formula described by Tomlinson et al.13 In the sleep benefit group, 16 patients were using levodopa and 9 patients (also) used dopamine agonists. In the group without sleep benefit, 19 patients used levodopa and 9 patients (also) used dopamine agonists. Both patients and controls were allowed to take other prescribed drugs. During the stay at the sleep lab, subjects were not allowed to drink any caffeine or alcohol containing drinks.

**Measures**

**Motor Tasks**

In the modified Perdue pegboard task, the time needed to place eight pegs from one hole to the next using one hand was measured. In the finger tapping task, the number of taps in 30 sec and the number of errors (pressing the 2 keys simultaneously) were registered. These finger tapping scores were automatically converted into a number of cycles (Hz). Both tasks were performed with both hands separately using a computer-based device (part of the At-Home Testing Device, Intel, courtesy of the Kinetics Foundation).9 Subjects practiced the tasks, alternating both hands, until scores reach asymptotic levels, with a minimum of 4 practice trials.

**Subjective Assessment of Functioning after Sleep**

The symptom diary was based on the SCOPA Diary Card (SCOPA DC),14 a validated instrument to assess changes in motor functioning during the day. Patients indicated on a 4-point Likert scale how well they could perform 3 activities, i.e., walking, changing position, and using their hands, a higher score indicating more difficulties in performance. These activities were proven to give a reliable indication of general motor functioning.14 The scores on different items were added to obtain one subjective motor score. In addition, the question on sleep quality from the SCOPA DC was used and we added an extra question on feeling rested upon awakening. Mood/vigilance ratings were obtained using a 16-item visual analogue scale containing 3 factors: alertness, calmness, and contentedness.15

**Neuropsychological Tasks**

To assess baseline neuropsychological functions, a battery of tasks was used: Beck Depression Inventory (BDI),16 Mini-Mental State Examination (MMSE),17 Frontal Assessment Battery (FAB)18; and premorbid intelligence levels were assessed using the Dutch version of the National Adult Reading Test (DART).19,20

**Polysomnography**

All sleep was polysomnographically monitored using a dedicated recording system (Compumedics Grael PSG, Compumedics, USA). PSG registration included standard 6-channel electroencephalography and electromyography of m. submentalis. Sleep stages were scored according to the AASM 2007 criteria21 using ProFusion software (ProFusion sleep 3 [build 392], Compumedics, USA). The main sleep outcomes were total sleep time, sleep efficiency, and sleep latency.

**Analyses**

All analyses were performed separately for night sleep and afternoon nap. The motor tasks and subjective measures on motor function and mood/vigilance were analyzed using repeated measures ANOVA, with the between-subject factor “group” (subjective sleep benefit, no sleep benefit, healthy controls) and one within-subject factor “sleep” (before sleep vs. after sleep). Sleep benefit was defined as a group by sleep interaction in these ANOVA models. Correlation analyses were performed using partial correlations controlled for “group.” Alpha was set to 0.01 in all analyses regarding multiple comparisons. All analyses were performed in SPSS version 20 for Windows.

**RESULTS**

Characteristics of the participants, baseline motor scores, and scores on the neuropsychological examination can be found in Table 1. The patient groups did not differ from each other, except that patients with sleep benefit tended to have longer disease duration (t = 2.56, P = 0.015). There was a trend towards higher LED in the sleep benefit group (t = 2.046, P = 0.05). However, there were no between group differences in the proportions of patients using extended release L-dopa, dopamine agonists, or COMT inhibitors. Patients had higher scores on the Beck depression inventory than the healthy controls (healthy controls vs. sleep benefit t = 4.84, P < 0.001, healthy controls vs. no-sleep benefit t = 6.18, P < 0.001 ). The no-sleep benefit group scored slightly lower on the Frontal Assessment Battery (FAB) than healthy controls (t = −3.33, P = 0.002); however, the group reporting sleep benefit showed no significant differences on the FAB when compared to healthy controls.

There were no between group differences in total sleep time, sleep stages, sleep efficiency, or sleep latency for night sleep nor afternoon nap (Table 2). There were also no differences in subjective ratings of sleep quality and feeling rested after sleep (night sleep and nap).
There was a small overall effect of night sleep on the pegboard task (F_{2,55} = 9.695, P = 0.003); subjects were on average slower in the morning. However, for the finger tapping tasks, there was no overall difference in evening and morning performance. Patients were slower than healthy controls on both tasks (P < 0.001; Finger tapping: F_{2,55} = 450.3, P = 0.002). There was no significant overall effect of sleep on both tasks, nor was there a group difference in the change in performance (no group*sleep interaction). There was no correlation between sleep time or efficiency and the difference in scores on either of the motor tasks, for both night sleep and the afternoon nap, nor did any of the sleep architecture measures show such an effect.

We did a subgroup analysis with only the 11 patients that reported subjective sleep benefit in both the sleep benefit questionnaire and symptom diary, hypothesizing that these patients had the clearest subjective sleep benefit. However, when comparing this subgroup with patients without subjective sleep benefit and healthy controls, this yielded comparable results.

### Subjective Measures

#### Motor Symptom Diary

Patients had higher (worse) scores in the motor symptom diary than healthy controls (night: F_{2,55} = 22.4, P < 0.001; healthy controls vs. sleep benefit P < 0.001, healthy controls vs no-sleep benefit P = 0.001; nap: F_{2,55} = 15.2, P < 0.001; healthy controls vs. sleep benefit P < 0.001, healthy controls vs no-sleep benefit P = 0.01, see also Figure 3). Patients in the sleep benefit group tended to have higher (worse) diary scores than patients in the no sleep benefit group (night: P = 0.012 nap: P = 0.031, Figure 3). We did not find a main effect of sleep on subjective motor scores after either night sleep or afternoon nap. There was also no group difference in the over-sleep change in subjective motor function (no group*sleep interaction). The correlation between the subjective motor score and the pegboard test, calculated using all available timepoints (before and after night and daytime sleep) was r_{p} = 0.43 (P < 0.001) and between the subjective motor score and the finger tapping test was r_{p} = −0.30 (P < 0.0001).

### Motor Tasks

The results of the motor tasks can be found in Figure 2. There was a small overall effect of night sleep on the pegboard task (F_{2,55} = 9.695, P = 0.003); subjects were on average slower in the morning. However, for the finger tapping tasks, there was no overall difference in evening and morning performance. Patients were slower than healthy controls on both tasks (P < 0.001; Finger tapping: F_{2,55} = 406.5, P < 0.001). For both tasks the overnight change in performance did not differ between the groups (no group*sleep interaction).

### Table 1—Descriptive demographics and clinical disease characteristics of study sample.

<table>
<thead>
<tr>
<th></th>
<th>Sleep Benefit</th>
<th>No Sleep Benefit</th>
<th>Healthy Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>18</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Men, n (%)</td>
<td>6 (35%)</td>
<td>14 (70%)</td>
<td>11 (58%)</td>
</tr>
<tr>
<td>Age, years</td>
<td>61.0 ± 5.9</td>
<td>63.2 ± 7.8</td>
<td>58.5 ± 7.5</td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>7.7 ± 4.3</td>
<td>4.6 ± 2.7</td>
<td>na</td>
</tr>
<tr>
<td>Age onset, years</td>
<td>52.3 ± 7.7</td>
<td>57.0 ± 7.7</td>
<td>na</td>
</tr>
<tr>
<td>LED, mg/day</td>
<td>777 ± 384</td>
<td>542 ± 270</td>
<td>na</td>
</tr>
<tr>
<td>MMSE</td>
<td>28.18 ± 2.2</td>
<td>27.75 ± 1.9</td>
<td>28.84 ± 1.2</td>
</tr>
<tr>
<td>FAB</td>
<td>16.06 ± 1.5</td>
<td>15.25 ± 2.3</td>
<td>17.16 ± 0.9</td>
</tr>
<tr>
<td>DART, IQ estimate</td>
<td>111.18 ± 17.7</td>
<td>108.85 ± 17.5</td>
<td>105.84 ± 18.4</td>
</tr>
<tr>
<td>BDI</td>
<td>10.12 ± 6.5</td>
<td>8.75 ± 3.8</td>
<td>2.68 ± 2.4</td>
</tr>
<tr>
<td>Baseline PGT, sec</td>
<td>19.5 ± 3.9</td>
<td>18.5 ± 3.3</td>
<td>14.3 ± 1.2</td>
</tr>
<tr>
<td>Baseline FTT, cycles</td>
<td>75.2 ± 27.2</td>
<td>75.4 ± 44.7</td>
<td>94.2 ± 26.4</td>
</tr>
</tbody>
</table>

Values are presented as mean ± standard deviation unless otherwise specified. The two patient groups did not significantly differ on the presented variables, except for disease duration. This is in line with previous findings on sleep benefit. LED, levodopa equivalent dose; MMSE, Mini Mental State Examination; FAB, Frontal Assessment Battery; DART, Dutch Adult Reading Test; BDI, Beck Depression Inventory; PGT, pegboard task; FTT, finger tapping task.

### Table 2—Sleep parameters.

<table>
<thead>
<tr>
<th></th>
<th>Sleep Benefit</th>
<th>No Sleep Benefit</th>
<th>Healthy Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Night</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total sleep time, min</td>
<td>356 ± 96</td>
<td>366 ± 98</td>
<td>406 ± 44</td>
</tr>
<tr>
<td>N1, % of TST</td>
<td>12.5 ± 16.1</td>
<td>8.0 ± 5.1</td>
<td>7.8 ± 3.8</td>
</tr>
<tr>
<td>N2, % of TST</td>
<td>48.5 ± 12.55</td>
<td>51.3 ± 8.7</td>
<td>50.2 ± 11.0</td>
</tr>
<tr>
<td>N3, % of TST</td>
<td>26.4 ± 11.3</td>
<td>25.8 ± 10.3</td>
<td>24.7 ± 11.0</td>
</tr>
<tr>
<td>REM, % of TST</td>
<td>12.6 ± 8.8</td>
<td>14.8 ± 6.8</td>
<td>18.1 ± 6.1</td>
</tr>
<tr>
<td>Sleep efficiency, %</td>
<td>75.4 ± 17.8</td>
<td>76.8 ± 18.6</td>
<td>83.3 ± 6.3</td>
</tr>
<tr>
<td>Sleep latency, min</td>
<td>32 ± 64</td>
<td>25 ± 31</td>
<td>12 ± 10</td>
</tr>
<tr>
<td>Nap</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total sleep time, min</td>
<td>46 ± 24</td>
<td>45 ± 26</td>
<td>50 ± 19</td>
</tr>
<tr>
<td>N1, % of TST</td>
<td>19.2 ± 19.1</td>
<td>19.2 ± 24.1</td>
<td>16.3 ± 20.3</td>
</tr>
<tr>
<td>N2, % of TST</td>
<td>55.2 ± 19.7</td>
<td>53.3 ± 25.0</td>
<td>49.9 ± 21.6</td>
</tr>
<tr>
<td>N3, % of TST</td>
<td>22.9 ± 23.7</td>
<td>25.1 ± 25.3</td>
<td>30.7 ± 22.3</td>
</tr>
<tr>
<td>REM, % of TST</td>
<td>2.7 ± 6.0</td>
<td>2.4 ± 7.4</td>
<td>3.0 ± 6.7</td>
</tr>
<tr>
<td>Sleep efficiency, %</td>
<td>58.5 ± 28.5</td>
<td>58.1 ± 26.1</td>
<td>65.6 ± 20.5</td>
</tr>
<tr>
<td>Sleep latency, min</td>
<td>8.6 ± 7.4</td>
<td>11.6 ± 10.7</td>
<td>8.3 ± 8.2</td>
</tr>
</tbody>
</table>

Values are presented as mean ± standard deviation. There were no significant differences between the sleep benefit and no-sleep benefit groups and between both of these groups and controls. TST, total sleep time.
Mood/Vigilance Rating Scales

There was no effect of sleep on the mood/vigilance scales for night sleep or afternoon nap. There was also no group difference in the over-sleep change in mood/vigilance (no group*sleep interaction). The healthy controls felt better than both patient groups (P < 0.005 for all scales, see also Table 3); however, the patient groups did not differ. The mood/vigilance rating scores did not correlate with the scores on the motor tasks.

DISCUSSION

The existence of subjective sleep benefit in Parkinson disease has been reported repeatedly in the literature. However, only few studies assessed whether sleep benefit is also associated with an objective improvement in motor symptoms. Here we used two quantitative motor tasks to assess sleep benefit in Parkinson patients. We showed that there was no objective sleep-related improvement in Parkinson signs in patients that declared to experience subjective sleep benefit. As expected, patients with and without subjective sleep benefit were slower on the quantified motor tasks than healthy controls. However, patients with or without sleep benefit did not differ in task performance after sleep.

We examined whether the lack of objective sleep benefit could be explained by the quality of the intervening sleep episodes. If “sleep benefit” is a real phenomenon, qualitatively better sleep should result in greater benefit for patients. Objective and subjective sleep quality did not differ between groups, and both nighttime sleep and afternoon naps were similar among groups. This shows that all groups achieved a good amount of sleep, excluding the possibility that lack of actual sleep explained the negative findings. Some studies suggested that sleep benefit might be related to poorer sleep. However, we found no support for this hypothesis. Taken together,
our results suggest that the quality of the preceding period of sleep does not determine the occurrence of sleep benefit either way, at least not for the range of sleep qualities achieved in this experimental setting.

Patients with subjective sleep benefit may also simply feel better after sleep. However, we did not find differences in subjective mood/vigilance and subjective sleep quality among patient groups. Although there was no change in subjective motor scores after sleep in patients with or without subjective sleep benefit, patients with sleep benefit tended to rate their motor signs as worse than patients without sleep benefit. So, the diary scores were not simply a reflection of mood/vigilance at the moment of testing. Moreover, the quantitative motor performance correlated with the subjective motor evaluation whereas the other subjective measures did not correlate with qualitative motor performance.

During the study, patients were not allowed to take Parkinson medication, so they were in the “off” state. We chose this approach because medication could mask possible sleep benefit. Furthermore, the exact influence of medication on motor functioning is difficult to define. Because of the large variability in medication we decided to test all patients without medication. There was a trend towards more medication use in patients with sleep benefit, so they possibly experienced a greater medication withdrawal effect. However, this was not reflected by the quantitative motor scores, nor by the mood/vigilance scores.

The leading hypothesis on the mechanism of sleep benefit states that dopamine storages in nigral neuronal terminals are replenished during sleep. According to this hypothesis, the presence of sleep benefit should have been more clear without medication, as its effect would not be masked by dopaminergic medication. As we did not find an objective sleep benefit effect, this hypothesis seems less likely. It could also be that sleep benefit is an overnight medication effect, for example caused by extended release L-dopa or longer acting dopamine agonists. In our patients, there was a trend toward more daily L-dopa equivalent medication use in the sleep benefit group, but the use of different types of medication did not differ between patient groups. However, we acknowledge that our study was designed to assess the effect of sleep and not the effect of medication. Therefore, the exact influence of medication on (fluctuations in) motor function remains to be studied formally using a design dedicated to diurnal medication effects.

As sleep benefit is a temporary phenomenon, we decided not to use an additional clinical examination to assess Parkinson signs. When performing an extensive examination such as the UPDRS, possible sleep benefit effects could have disappeared before finishing the complete test. As the aim of this study was to assess differences in objective motor performance, we chose to use two quick, quantitative motor tests, which do correlate well with the UPDRS.

### Table 3—Subjective measures.

<table>
<thead>
<tr>
<th></th>
<th>Sleep Benefit</th>
<th>No Sleep Benefit</th>
<th>Healthy Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-sleep</td>
<td>Post-sleep</td>
<td>Pre-sleep</td>
</tr>
<tr>
<td>Night</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alertness</td>
<td>4.4 ± 0.3</td>
<td>4.4 ± 0.3</td>
<td>3.5 ± 0.3</td>
</tr>
<tr>
<td>Calmness</td>
<td>4.1 ± 0.6</td>
<td>3.5 ± 0.6</td>
<td>3.7 ± 0.4</td>
</tr>
<tr>
<td>Contentedness</td>
<td>3.2 ± 0.4</td>
<td>3.2 ± 0.4</td>
<td>3.2 ± 0.4</td>
</tr>
<tr>
<td>Nap</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alertness</td>
<td>3.7 ± 0.3</td>
<td>3.4 ± 0.5</td>
<td>3.0 ± 0.4</td>
</tr>
<tr>
<td>Calmness</td>
<td>3.9 ± 0.5</td>
<td>3.1 ± 0.5</td>
<td>3.1 ± 0.4</td>
</tr>
<tr>
<td>Contentedness</td>
<td>2.7 ± 0.3</td>
<td>2.6 ± 0.4</td>
<td>2.7 ± 0.3</td>
</tr>
</tbody>
</table>

Values are presented as mean ± standard error. The possible mood/vigilance rating scores range from 0 (very alert/calm/contented) to 10 (not alert/calm/contented at all).
We evaluated only one night of sleep and one daytime nap. There could be some day-to-day variation in the occurrence of sleep benefit. None of the patients reported improvement every night in the 7-day screening diary used for recruitment. So, even the patients with clear subjective sleep benefit had nights without improvement in the symptom diary. A longitudinal study including more nights and naps could account for this variation. There was some variability in results; in both patient groups there were patients who improved and patients who worsened on the motor tasks. However, the individual differences in performance over sleep were small, and even in the healthy control group there were subjects who improved and subjects who deteriorated a similar amount after a period of sleep. So the observed differences in performance are probably not Parkinson-specific, but represent a naturally occurring effect throughout the population.

It was shown before that patients with subjective sleep benefit sometimes seem to misperceive their motor functioning at awakening. Högl et al. reported that “several patients with sleep benefit praised their morning mobility as unrestrained [...] although their overall appearance and objective evaluation using UPDRS were indicative of being in the “off” state.” Our results also showed that the subjective experience of sleep benefit did not match actual improvement in motor functioning. Our results combined with these previous findings offer further evidence that sleep benefit is mainly a subjective phenomenon that is not related to a Parkinson-specific improvement in motor function. Nevertheless, subjective sleep benefit is reported in the literature by a consistently high number of patients. The origin and underlying mechanism of this subjective sleep benefit should be the focus of future research.

DISCLOSURE STATEMENT
This was not an industry supported study. This study was supported by a VIDI research grant to Dr. Overeem from the Netherlands Organization for Scientific Research (grant no. 016.116.371). Dr. Bloem has received research support from the Netherlands Organization for Scientific Research, Prinses Beatrix Fonds, Stichting Internationaal Parkinson Fonds, Alkemade Keuls Fonds, and Michael J Fox foundation (all unrelated to this study), and has consulted for Danone, Glaxo-Smith-Kleine, and UCB Pharma (all unrelated to this study). Dr. Overeem has received research support, consulted for, been on the speaker’s bureau of, and received a travel grant from UCB Pharma (all unrelated to this study) The other authors have indicated no financial conflicts of interest.

REFERENCES